CardioCareLive

Scientific Advisory Board

The Scientific Advisory Board (SAB) is the team of distinguished academic researchers and clinicians responsible for conducting scientific and/or clinical review of all CardioCareLive programs. CardioCareLive is committed to presenting the most up-to-date and relevant programs to the cardiovascular community, and the experience and insights the SAB provides ensures that all programs meet that high standard. Members of the SAB include:

Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC
Seth J. Baum,
MD, FACC, FACPM, FAHA, FNLA, FASPC
President,
Chief Medical Officer,
Founder at Excel Medical Clinical Trials, LLC
Dr. Seth J. Baum, a graduate of Columbia College and Columbia College of Physicians and Surgeons, completed training in Internal Medicine, Cardiology, Interventional Cardiology, and Electrophysiology. He has directed and founded multiple Cardiac Catheterization and Electrophysiology laboratories. Dr. Baum has worked extensively in Integrative Cardiology, directing the Boca Raton division of Harvard’s Mind/Body Medicine Institute.
Dr. Baum is a fellow of the American College of Cardiology, the American Heart Association, the American College of Preventive Medicine, the National Lipid Association, and the American Society for Preventive Cardiology. He is a Founding Physician/Scientist Member of the Society for Cardiovascular CT and is board certified in Cardiovascular CT. Dr. Baum served as treasurer of the International Society for the Study of Fatty Acids and Lipids. He founded and directs the Women’s Preventive Cardiology program at Boca Raton Regional Hospital. He is the President of the American Society for Preventive Cardiology (ASPC). Annually, Dr. Baum chairs the ASPC’s Conference on CVD Prevention. Dr. Baum is the Secretary/Treasurer of the Board of Directors of the FH Foundation. He sits on the American Heart Association’s Council for Epidemiology and Prevention as well as its Leadership committee, the Interdisciplinary Council for Prevention, and the Prevention Science Committee. He has written numerous peer reviewed papers as well as two books, The Total Guide to a Healthy Heart, and Age Strong, Live Long; Lessons from my Patients. In 2013 he was awarded Cleveland Heart Lab’s “Heart Award” for lifelong dedication to Preventive Medicine. Dr. Baum is the Founder and Chief Medical Officer of Excel Medical Clinical Trials, LLC, a consortium of clinicians dedicated to the safe and professional conduct of high-level scientific trials.
Clinical Affiliate Professor of Medicine at FAU Medical School, Dr. Baum has a practice in Boca Raton, Florida that is devoted solely to Clinical Lipidology – he is board certified by the American Board of Clinical Lipidology – and Cardiovascular Disease Prevention. Dr. Baum also founded and directs the only lipoprotein apheresis program in southeast Florida. He lectures both nationally and internationally, emphasizing Familial Hypercholesterolemia, ASCVD prevention, lipid disorders and evolving therapies, Integrative Cardiology, sex distinctions in CVD, and omega-3 fatty acids.

Gregg C. Fonarow, MD
Gregg C. Fonarow
MD
Director, Ahmanson-UCLA Cardiomyopathy Center
Co-Chief, Division of Cardiology,
David Geffen School of Medicine
UCLA
Dr. Gregg C. Fonarow serves as Director of the Ahmanson-UCLA Cardiomyopathy Center, Co-Chief of UCLA’s Division of Cardiology, and Co-director of UCLA’s Preventative Cardiology Program. He attained the rank of Professor of Medicine in 2003. He was awarded the Eliot Corday Chair in Cardiovascular Medicine and Science in 2003. His research interests center on heart failure management, preventative cardiology, disease management, and implementing treatment systems to improve clinical outcome. Dr Fonarow has published over 800 research studies and clinical trials in heart failure management, preventative cardiology, and outcomes research. New therapies and management strategies for advanced heart failure and research into the pathophysiology of this disease are conducted at UCLA under his direction. He has also developed and successfully implemented a comprehensive atherosclerosis treatment program at the UCLA Medical Center (Cardiovascular Hospitalization Atherosclerosis Management Program: CHAMP). Dr Fonarow is on the steering committee for the American Heart Association’s Get with the Guidelines (GWTG) program, ADHERE Registries, and OPTIMIZE-HF. He serves as a reviewer and on the editorial boards of a number of leading cardiovascular journals. Dr. Fonarow received the outstanding UCLA Cardiology Faculty Teaching Award in 1997 and was honored by the American College of Cardiology with the W. Proctor Harvey Young Teacher Award in 1998. He received an AHA Award of Meritorious Achievement in 2004.

Peter A. McCullough, MD, MPH, FACP, FACC, FCCP, FAHA, FNKF, FNLA, FCRSA
Peter A. McCullough,
MD, MPH, FACP, FACC, FCCP, FAHA, FNKF, FNLA, FCRSA
After receiving a bachelor’s degree from Baylor University, Dr. McCullough completed his medical degree as an Alpha Omega Alpha graduate from the University of Texas Southwestern Medical School in Dallas. He went on to complete his internal medicine residency at the University of Washington in Seattle, cardiology fellowship including service as Chief Fellow at William Beaumont Hospital, and master’s degree in public health at the University of Michigan. Dr. McCullough is a consultant cardiologist and Vice Chief of Medicine at Baylor University Medical Center in Dallas, TX. He is a Principal Faculty in internal medicine for the Texas A & M University Health Sciences Center. Dr. McCullough is an internationally recognized authority on the role of chronic kidney disease as a cardiovascular risk state with > 1000 publications and > 500 citations in the National Library of Medicine. His works include the “Interface between Renal Disease and Cardiovascular Illness” in Braunwald’s Heart Disease Textbook. Dr. McCullough is a recipient of the Simon Dack Award from the American College of Cardiology and the International Vicenza Award in Critical Care Nephrology for his scholarship and research. Dr. McCullough is a founder and current president of the Cardiorenal Society of America, an organization dedicated to bringing cardiologists and nephrologists together to work on the emerging problem of cardiorenal syndromes. His works have appeared in the New England Journal of Medicine, Journal of the American Medical Association, Lancet and other top-tier journals worldwide. He is the co-editor of Reviews in Cardiovascular Medicine, and associate editor of the American Journal of Cardiology and Cardiorenal Medicine. He serves on the editorial boards of multiple specialty journals. Dr. McCullough has made presentations on the advancement of medicine across the world and has been an invited lecturer at the New York Academy of Sciences, the National Institutes of Health, U.S. Food and Drug Administration (FDA), European Medicines Agency, and the U.S. Congressional Oversight Panel.

James L. Januzzi, Jr., MD, FACC, FESC
James L. Januzzi, Jr.
MD, FACC, FESC
Hutter Family Professor of Medicine Harvard Medical School
James L. Januzzi, MD, is the Hutter Family Professor of Medicine at Harvard Medical School, a staff cardiologist at Massachusetts General Hospital, and senior cardiometabolic faculty at Baim Institute for Clinical Research in Boston. His research has contributed to the understanding of cardiac biomarker testing, where his studies have set international standards for use in diagnosis, prognosis, and management of patients suffering from acutely decompensated heart failure, chronic heart failure as well as those with acute coronary syndromes. Dr Januzzi has published hundreds of manuscripts, book chapters and review articles, has edited two textbooks on cardiac biomarker testing, and is on the editorial board of numerous scientific journals. He earned his MD from New York Medical College.